Clinical trials: Prostate Cancer Stage IV
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
This randomized phase II trial studies if enzalutamide added to standard luteinizing hormone-releasing hormone (LHRH) analogue therapy will improve effects against prostate cancer compared to the standard therapy of LHRH analogue…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02058706
- Testing
- enzalutamide, bicalutamide, orchiectomy
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Bone Metastases, Castrate-resistant Prostate Cancer
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an…
- Conditions
- Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01599793
- Testing
- cabozantinib, laboratory biomarker analysis, magnetic resonance imaging
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Prostate Cancer
Efavirenz in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate…
- Trial name
- FAVE (NCT00964002)
- Testing
- efavirenz
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Institut Bergonié
Prostate Cancer, Adenocarcinoma of the Prostate
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer
- Trial name
- NCT00879619
- Testing
- sunitinib malate, docetaxel, prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- John P. Fruehauf
Metastatic Cancer, Prostate Cancer
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.
- Trial name
- NCT00634582
- Testing
- paricalcitol, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did…
- Trial name
- NRR (NCT00246753)
- Testing
- lapatinib ditosylate
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03873805
- Testing
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
This phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen…
- Trial name
- A-DREAM (NCT05241860)
- Testing
- Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration
- Where
- 326 sites in United States
- Volunteers
- 79 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Vitamin D in Treating Patients With Prostate Cancer
RATIONALE: Vitamin D may be effective in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying how well 4 different doses of vitamin D works in treating patients with prostate cancer.
- Trial name
- NCT00524680
- Testing
- cholecalciferol
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Roswell Park Cancer Institute
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase II trial studies how well hormone therapy and intensity-modulated radiation therapy work in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT00544830
- Testing
- Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Carcinoma
- Trial name
- NCT02499835
- Testing
- Pembrolizumab, pTVG-HP Plasmid DNA Vaccine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004054
- Testing
- bicalutamide, estramustine phosphate sodium, etoposide
- Where
- 54 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
This is a multicenter phase 2b study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for…
- Trial name
- NCT04028388
- Testing
- Docetaxel in Parenteral Dosage Form, ModraDoc006/r
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 135 people
- Sponsor
- Modra Pharmaceuticals
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
This pilot clinical trial studies docetaxel and carboplatin in treating patients with castration resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic)…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02598895
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Washington
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01866423
- Testing
- orteronel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
RATIONALE: Specialized radiation therapy that delivers a high-dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00528866
- Testing
- bicalutamide, docetaxel, flutamide
- Where
- 70 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Radiation Therapy Oncology Group
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center